Last reviewed · How we verify
Gapabentin
Gapabentin, marketed by Rutgers, The State University of New Jersey, is a drug with a key composition patent expiring in 2028. The primary strength of Gapabentin lies in its established market presence, leveraging its current marketed status. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Gapabentin |
|---|---|
| Also known as | Neurontin |
| Sponsor | Rutgers, The State University of New Jersey |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP) (NA)
- Effect of Gabapentin on Orthopedic Pain (PHASE4)
- Cancer in Patients With Gabapentin (GPRD)
- Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
- Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |